Kite nails down TCR IP in new licensing pact

Kite Pharma ($KITE) has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens. It is paying the NIH an unspecified upfront and milestones in a deal that covers lung, pancreatic, gastric and breast cancers, among others. Kite has long had a very close working relationship with Steven Rosenberg at the NCI. Release

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.